Population
70-year-old woman with breast cancer (n=1)
Design
Case_report
Follow-up
2 months
Authors
Loading...
Supports reversibility of epirubicin cardiotoxicity with intensive HF therapy; hypothesis-generating and should not yet change practice.
This case report highlights that epirubicin-induced subacute cardiotoxicity can be reversible with intensive heart failure treatment.
Koitabashi et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: